{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:01:45Z","timestamp":1787760105813,"version":"build-2784847793"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ejpn.2024.08.010","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T02:37:11Z","timestamp":1725417431000},"page":"A3-A4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Tocilizumab in acute necrotizing encephalopathy (ANE): How much, how soon, and will it improve outcomes beyond survival?"],"prefix":"10.1016","volume":"52","author":[{"given":"Velda X.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2024.08.010_bib1","first-page":"1","article-title":"International consensus definitions for infection-triggered encephalopathy syndromes","volume":"00","author":"Sakuma","year":"2024","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2024.08.010_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejpn.2024.07.009","article-title":"Acute necrotizing encephalopathy infected with the SARS-CoV-2 in children: case series and literature review of clinical outcomes with the use of Tocilizumab","volume":"52","author":"Ma","year":"2024","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.08.010_bib3","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200186","article-title":"Defining the clinicoradiologic syndrome of SARS-CoV-2 acute necrotizing encephalopathy: a systematic review and 3 new pediatric cases","volume":"11","author":"Lee","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ejpn.2024.08.010_bib4","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.15536","article-title":"Factors associated with outcomes of severe acute necrotizing encephalopathy: a multicentre experience in Malaysia","author":"Lee","year":"2023","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.ejpn.2024.08.010_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/jcph.1703","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous sarilumab and intravenous tocilizumab following single-dose administration in patients with active rheumatoid arthritis on stable methotrexate","volume":"61","author":"Paccaly","year":"2021","journal-title":"J. Clin. Pharmacol."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379824001314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T22:11:10Z","timestamp":1764627070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379824001314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":5,"alternative-id":["S1090379824001314"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.08.010","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tocilizumab in acute necrotizing encephalopathy (ANE): How much, how soon, and will it improve outcomes beyond survival?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2024.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}